Ayse Ayzit Kilinc Sakalli

Dr. Ayse Ayzit Kilinc Sakalli


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2019 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DDDeniz Dogru
Deniz Dogru
ECErkan Cakir
Erkan Cakir
AAAyse Tana Aslan
Ayse Tana Aslan
Nazan CobanogluNazan Cobanoglu
Nazan Cobanoglu
SPSevgi Pekcan
Sevgi Pekcan
UÖUğur Özçelik
Uğur Özçelik

29 November 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ASAyse Ayzit Kilinc Sakalli
Ayse Ayzit Kilinc Sakalli
AAAsli Arslan
Asli Arslan
MYMehmet Yildiz
Mehmet Yildiz
MKMine Kucur
Mine Kucur
AAAmra Adrovic Adrovic
Amra Adrovic Adrovic
OKOzgur Kasapcopur
Ozgur Kasapcopur


25 September 2021 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
CYCansu Yilmaz Yeğit
Cansu Yilmaz Yeğit
ASAyse Ayzit Kilinc Sakalli
Ayse Ayzit Kilinc Sakalli
SOSinem Can Oksay
Sinem Can Oksay
FUFusun Unal
Fusun Unal
HYHakan Yazan
Hakan Yazan
EEEla Erdem Eralp
Ela Erdem Eralp

26 May 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
Nazan CobanogluNazan Cobanoglu
Nazan Cobanoglu
UÖUğur Özçelik
Uğur Özçelik
ECErkan Cakir
Erkan Cakir
AAAyse Tana Aslan
Ayse Tana Aslan
SPSevgi Pekcan
Sevgi Pekcan
DDDeniz Doğru
Deniz Doğru

Verified
Journal Article
Open access
PDF file
FHFatih Haslak
Fatih Haslak
SVSevki Erdem Varol
Sevki Erdem Varol
AGAybuke Gunalp
Aybuke Gunalp
OKOzge Kaynar
Ozge Kaynar
MYMehmet Yildiz
Mehmet Yildiz
OKOzgur Kasapcopur
Ozgur Kasapcopur
(1) Background: We aimed to describe the clinical features and outcomes of coronavirus disease-2019 (COVID-19) in children and late adolescents with inflammatory rheumatic diseases (IRD) and to measure their severity risks by comparing them with healthy children. (2) Methods: Among children and late adolescents found to be severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) positive via polymerase chain reaction (PCR) test, IRD patients with an at least six-months follow-up duration, and healthy children were included in the study. Data were obtained retrospectively. (3) Results: A total of 658 (339 (51.5%) females) (healthy children: 506, IRD patients: 152) subjects were included in the study. While 570 of 658 (86.6%) experienced COVID-19-related symptoms, only 21 (3.19%) required hospitalization with a median duration of 5 (1–30) days. Fever, dry cough, and fatigue were the most common symptoms. None of evaluated subjects died, and all recovered without any significant sequelae. The presence of any IRD was found to increase the risk of both hospitalization (OR: 5.205; 95% CI: 2.003–13.524) and symptomatic infection (OR: 2.579; 95% CI: 1.068–6.228). Furthermore, increasing age was significantly associated with symptomatic infection (OR: 1.051; 95% CI: 1.009–1.095). (4) Conclusions: Our study emphasizes that pediatric rheumatologists should monitor their patients closely for relatively poor COVID-19 outcomes.